CORE B - Hematology, Chemistry and Coagulation Core

CORE B - 血液学、化学和凝血核心

基本信息

批准号：
10171425
负责人：
Dzung T Le
金额：
$ 22.66万
依托单位：
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-07-15 至 2026-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10171425
关键词：
Address Albumins Alkaline Phosphatase Anticoagulants Anticoagulation Antiplasmin Antithrombins Bicarbonates Biological Assay Blood Blood Cells Blood Coagulation Disorders Blood Coagulation Factor Blood Platelets Blood specimen Calcium Cellular Morphology Chemicals Chlorides Clinical Coagulation Process Complete Blood Count Core Facility Creatinine Data Electrolytes Enzymes Erythrocyte Indices Erythrocytes Factor XI Fibrin fragment D Fibrinogen Fibrinolysis Geography Giemsa stain Glucose Glycoproteins Hematology Hematopoietic System Hemostatic Agents Hemostatic function Heparin High Density Lipoproteins Hour Human Human Volunteers Immunoglobulin G Immunoglobulins Infection Inflammation Kidney Leukocytes Lipids Liver Low-Density Lipoproteins Measurement Measures Metabolic Metabolism Microscopic Morbidity - disease rate Morphology Mus Organ Pancreas Pathogenesis Pathway interactions Patients Phosphorus Plasma Platelet Count measurement Potassium Protein C Protein Glycosylation Protein S Proteins Prothrombin Red Blood Cell Count Sampling Sepsis Serology Serum Sodium Standardization Stratification TFPI Testing Thromboplastin Von Willebrand antigen Whole Blood antithrombin III-protease complex liver function mortality pathogen pathogenic bacteria peripheral blood platelet function programs total measurement Bilirubin

项目摘要

SUMMARY Core B will provide essential support for the projects to achieve their specific aims while addressing the central hypothesis of the program project, which is that “protein glycosylation and glycoprotein remodeling alter the coagulopathy and inflammation of sepsis".Core B will analyze blood or plasma samples from mice, patients with sepsis, and healthy human volunteers generated from the projects to detect any changes in the cellular components (hematology), chemical composition (Chemistry), and hemostatic status (Coagulation) that may take place in different experimental or clinical conditions.Core B will use defined panels of assays as an efficient way to detect potentially significant changes in experimental versus control studies. These panels are: 1. Hematology: Complete blood count with white cell subsets (differential count) and microscopic examination of peripheral blood smears for cellular morphology; 2. Chemistry: serum electrolytes, total protein, IgG immunoglobulin, liver enzymes (AST, ALT, ALP), and optionally lipids (LDL, HDL, TG) to evaluate the overall functions of the liver, pancreas, and kidney, as well as the general metabolic status; 3. Hemostasis: von Willebrand antigen (primary hemostasis), PT, APTT, clotting factors II, V, VII, VIII, IX, X, XI and XII, fibrinogen, and D-dimer or FDPs (coagulation), protein C, protein S, and antithrombin (anticoagulation), and antiplasmin (fibrinolysis). Additional tests that have been standardized in Core B such as thrombin-antithrombin complex, heparin anticoagulant activities, plasma tissue factor, tissue factor pathway inhibitor, whole blood platelet aggregometry and whole blood thromboelastograph will be available to all projects as needed.During the past four years, Core B has successfully used this approach to generate data of significant import to the program including the identification of multiple differences in mouse and human blood comparing infections of discrete pathogens implicating potential undiscovered pathways of pathogenesis with the possibility of stratification of sepsis among both species. This proposal focuses on continuing to provide these hematological analyses of mouse and human blood and plasma samples in support of the specific aims of the projects.

概括核心B将为项目提供基本的支持，以实现其特定目标，同时解决中心该计划项目的假设，即“蛋白质糖基化和糖蛋白重塑改变了脓毒症的凝血病和炎症。与败血症和健康的人类志愿者一起从项目中产生的，以检测细胞的任何变化成分（血液学），化学成分（化学）和止血状态（凝结）可能在不同的实验或临床状态下发生。核B将使用定义的测定面板作为检测实验研究与对照研究的潜在重大变化的有效方法。这些面板是： 1。血液学：白细胞亚群（差分计数）和微观检查的完全血液计数用于细胞形态的外周血涂片； 2。化学：血清电解质，总蛋白质，IgG 免疫球蛋白，肝酶（AST，ALT，ALP）和脂质（LDL，HDL，TG）评估总体肝脏，胰腺和肾脏的功能以及一般的代谢状态； 3。止血：冯 Willebrand抗原（原发性止血），PT，APTT，服装因子II，V，VII，VIII，IX，IX，X，XI和XII，纤维蛋白原，，以及D-二聚体或FDP（凝结），蛋白C，蛋白质S和抗凝血酶（抗凝）和抗蛋白酶（纤维蛋白溶解）。在核心B中已标准化的其他测试，例如凝血酶 - 抗凝结蛋白复合物，肝素抗凝活性，血浆组织因子，组织因子途径抑制剂，全血血小板所有项目都可以根据需要使用聚集体和全血栓弹仪。四年来，核心B已成功使用这种方法来生成对程序的重要导入数据包括鉴定小鼠和人体比较离散感染的多种差异病原体将潜在的未发现的发病机理隐含，并有分层的可能性这两种物种中的败血症。该提案着重于继续提供这些血液学分析小鼠和人类血液和血浆样品支持项目的具体目的。